122.36 -0.01 (-0.01%)
After hours: 7:50PM EDT
|Bid||122.37 x 100|
|Ask||122.59 x 200|
|Day's Range||121.45 - 123.18|
|52 Week Range||96.93 - 147.17|
|PE Ratio (TTM)||37.90|
|Earnings Date||Oct 26, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||148.62|
Biotechs have been big winners in 2017, but the group and several top stocks have been drifting lower, testing key levels. Biogen reports earnings Tuesday, with Amgen, Vertex, Gilead, Celgene and Alexion later this week.
Celgene abandoned a key drug application last week, sending the stock and sector into a tailspin that could signal an intermediate correction.
Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.
Celgene toppled to a four-month low Friday after it scrapped trials in Crohn's disease after a late-stage failure.
On another record day for the major benchmarks, shares of Skechers skyrocketed on earnings and Celgene tumbled after discontinuing a drug trial.
Shares of Celgene (CELG) plunged to the bottom of the S&P 500 today after the drug maker abandoned clinical trials testing its experimental drug Mongersen as a treatment for Crohn’s disease. The stock fell almost 10.8% to close at $121.33 on a day when the S&P 500 posted a 0.5% gain, making Celgene the worst-performing stock in the index. Mongersen was a high-profile drug in Celgene’s pipeline.
Stocks that moved substantially or traded heavily Friday: Celgene Corp., down $14.63 to $121.33 The drugmaker ended late-stage testing of a potential treatment for Crohn's disease. General Electric Co., ...
World stocks advanced, bond yields rose and the U.S. dollar strengthened on Friday on increased hopes President Donald Trump could make progress on his fiscal plans after the U.S. Senate approved a budget blueprint that paves the way for tax cuts. U.S. Republican Senator Rand Paul appeared to back the administration's sweeping tax cut plan, saying he was "all in" for massive tax cuts, even as the Senate passed a key budget measure without his support one day earlier.
Congress makes progress toward tax reform and Wall Street cheers. All major indexes secure new records heading into the weekend.
A disappointing late-stage trial failure is causing shares to tumble, but there's a lot going on at this company that could pan out for investors.
BMO Capital Markets’ M. Ian Somaiya takes a look at the biotech sector on Friday, writing that another strong quarter could help the stocks keep climbing. Somaiya writes that he expects solid results from ...